Novan Provides Enrollment Update and Announces New Corporate Headquarters
January 19, 2021 09:00 ET
|
Novan, Inc.
– B-SIMPLE4 pivotal Phase 3 study in molluscum contagiosum reaches 90% enrollment with topline data targeted for Q2 2021 – – Company secures new location to serve as corporate headquarters and to...
Novan Exceeds 60% Enrollment in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum
December 15, 2020 09:00 ET
|
Novan, Inc.
– Completion of patient enrollment targeted for Q1 2021 with readout of topline results targeted for Q2 2021 – – SB206, if approved, has the potential to meet an important need for the treatment of...
Tips To Avoid Spreading Molluscum Contagiosum; American Academy of Dermatology
December 08, 2020 14:30 ET
|
American Academy of Dermatology
ROSEMONT, Ill., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Molluscum contagiosum is a common and highly contagious skin condition caused by a virus. According to dermatologists from the American Academy of...
Novan to Present at the Virtual Investor KOL Roundtable
October 21, 2020 09:00 ET
|
Novan, Inc.
MORRISVILLE, N.C., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that members of management will participate in the Virtual Investor KOL...
Novan Provides Pipeline and Priority Development Programs Update
September 14, 2020 09:05 ET
|
Novan, Inc.
- Lead product candidate, SB206 currently being evaluated in B-SIMPLE4 pivotal Phase 3 study in molluscum contagiosum with topline data targeted for Q2 2021 - - In vitro assessments of ability of...
Novan Announces First Patient Enrolled and Dosed in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum
September 03, 2020 09:05 ET
|
Novan, Inc.
- Topline results targeted for Q2 2021, less than a year away - - SB206, if approved, has the potential to meet an important need for the treatment of molluscum, an area with no current FDA-approved...
Novan Initiates B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum
August 31, 2020 08:05 ET
|
Novan, Inc.
- Clinical sites actively enrolling patients - - SB206, if approved, has the potential to meet an important need for the treatment of molluscum, an area with no current FDA-approved treatment - ...
Tarsus Medical Group Launches a New Dermatological Medical Education Hub: LiVDerm
July 31, 2020 06:00 ET
|
LiVDerm
Boca Raton, July 31, 2020 (GLOBE NEWSWIRE) -- Tarsus Medical Group has announced the launch of LiVDerm: a new medical education hub dedicated to advancing higher standards of dermatology care. With...
Novan Anticipates Current Cash Position Provides Sufficient Capital to Conduct Additional SB206 Phase 3 Pivotal Trial
June 25, 2020 08:00 ET
|
Novan, Inc.
MORRISVILLE, N.C., June 25, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Company anticipates that its current cash position will be...
Novan to Present at Virtual Life Sciences Investor Forum on June 25
June 24, 2020 08:15 ET
|
Novan, Inc.
MORRISVILLE, N.C., June 24, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today announced that Paula Brown Stafford, the Company’s President and Chief Executive...